Navigation Links
Future MRSA Outbreaks in Schools are Preventable!
Date:10/22/2007

pump bottles (8/case) and a 500 mL. controlled dispensing system.

Forward-Looking Statements

This press release contains 'forward looking' statements within the meaning of Section 21A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbors created thereby. Such statements involve certain risks and uncertainties associated with an emerging company. Actual results could differ materially from those projected in the forward looking statements as a result of risk factors discussed in Skinvisible, Inc. reports on file with the U.S. Securities and Exchange Commission (including, but not limited to, a report on Form 10Q for the quarter ending June 30, 2007).

Corporate Contact:

Terry Howlett, President/CEO

Skinvisible Pharmaceuticals, Inc

Phone: 702-433-7154

Email: info@skinvisible.com


'/>"/>
SOURCE Skinvisible, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Low Birth Weight infants could have Problems in the Future
2. Eyes,The Window To The Future
3. Needle free future for diabetics
4. Oral memory indicates future Alzheimers patients
5. New Virus : A Threat In the Future?
6. Will Your Baby Grow Up To Be A Future Einstein ?
7. Genetic Pills A Future Thought
8. Prediction Of Disease In The Future Questioned
9. Asthmatics May Be At Risk for Lung Disease In The Future
10. Use Of Sunscreen In Childhood And Prevents Future Skin Cancer
11. Childrens Waistlines A Predictor Of Future Heart Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...rstCall/ -- Tempo Participacoes,S.A. (Bovespa: TEM...ding,provider of healthcare administration service... services, announces today its results for the fir...formation contained herein,except where otherwise...,accordance with Brazilian Stock Exchange Commissi...
(Date:5/15/2008)...sing in Targeting Cancer Cells, ...ay 15 /PRNewswire-FirstCall/ -- Abbott scientists,...everal investigative,compounds in the company,s on... Clinical Oncology (ASCO) Annual Meeting, schedule... ABT-263, a Bcl-2 family protein,antagonist, and A...
(Date:5/15/2008)...ng cancer treatment for each individual, researche...resented a study suggesting a simple blood test ca...cacy for patients with metastatic breast cancer. ,...to determine if a particular cancer treatment is w...y significant radiographic changes in tumor size o...
(Date:5/15/2008)...tCall/ -- Digital Power,Corporation (Amex: DPW ) ...cial results for the first quarter ended March 31,...000 for the quarter ended,March 31, 2008, an incre...last year. An operating loss of $165,000 for the f...operating profit of $25,000 for the same quarter,l...
Breaking Medicine News(10 mins):Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 2Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 3Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 4Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 5Health News:Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting 6Health News:Study suggests blood test can help improve treatment outcomes for breast cancer patients 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 2Health News:Digital Power Reports Financial Results for the First Quarter Ended March 31, 2008 3
... North America with an estimated 400,000 people fa...of these //people have their hearts pumping again ...of the main causes of death after the heart is res...esented at the 2006 Society for Academic Emergency...
...cos here have collapsed due to fasting in the past...fight against// reservation for backward classes w...ecision. "Ninety-four doctors have so far collapse...e hunger strike. Currently 35 of them are still si...
...people to get themselves screened for HIV, city-ru...criteria// for HIV testing. According to the new r...ent is not neccessary for voluntary HIV/AIDS testi...consent from the patient. This rule makes it the ...
...e discovered the cause for people to overeat. Scie...it's in the brain//. Researchers at the council's... the first neurobiological proof as to why some pe...research, published today in the Journal of Neuros...
Other Medicine News:Health News:Survival After Cardiac Arrest Is Aided By Cooling 2Health News:Despite Collapse Of The Medicos Strike To Continue Unabated 2Health News:Research Scans Explain Why People Crave For Food 2
(Date:5/15/2008)...Antiplatelet Therapy that, Combined, with Aspirin,...ix/Iscover and Aspirin, According to a New Rep...15 /- Decision Resources, one of the,...armaceutical and,healthcare issues, finds that Dai... in patient compared to Sanofi-Aventis/Bristol Mye...
(Date:5/15/2008)...ares Genous, Boston Scientific,s ...on Real-World Use of Genous, Stent,s Performance ... Dual-Antiplatelet ... OrbusNeich today announced,that multiple clinical...,support the use of the company,s Genous Bio-engin...
(Date:5/14/2008)...ire-FirstCall/ -- Progen,Pharmaceuticals Limited (...mpany has resumed patient enrolment in the phase 1...lyamine analogue, PG-11047 (formerly CGC-11047),fo...enced development of PG-11047 - the lead clinical,...owing its acquisition of,Cellgate, Inc earlier thi...
(Date:5/14/2008)... for cervical cancer prevention, GRAZ, Austria, M...xtended follow-up study show that GlaxoSmithKline ...ERVARIX(R) generates sustained high levels of,neut...rvical cancer-causing,human papillomavirus types f...f sustained neutralizing antibody levels observed ...
Breaking Medicine Technology:Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6EaglePicher Medical Power Names Joseph Marotta Vice President of Sales and Marketing 14008 1EaglePicher Medical Power Names Joseph Marotta Vice President of Sales and Marketing 14008 2Colon Cancer Screening Laws Now Cover Half of U S Population 3861 1Colon Cancer Screening Laws Now Cover Half of U S Population 3861 2Colon Cancer Screening Laws Now Cover Half of U S Population 3861 3Colon Cancer Screening Laws Now Cover Half of U S Population 3861 4Colon Cancer Screening Laws Now Cover Half of U S Population 3861 5DURECT to Participate in Cowen Annual Healthcare Conference 14005 1Outcomes Improve for Non Hodgkin Lymphoma Patients 14002 1Outcomes Improve for Non Hodgkin Lymphoma Patients 14002 2
...LIS, France, May 11, 2007 /PRNewswire-FirstCall/ -...ate on the phase 2a,study for NCX 1000, which is c...harma Inc. A preliminary analysis of 11 patients,...nsion confirmed,the safety profile of NCX 1000 but...ort the continuation of this clinical trial. As a,...
...(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma,...peutics for the,treatment of musculoskeletal, meta... results of a preclinical study with,ACE-031 that ...se,muscle mass and strength in normal mice and in ...its negative regulators of muscle,to increase musc...
Other Medicine Technology:NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 2NicOx Provides an Update on the Phase 2a Study for NCX 1000,Conducted With Axcan 3Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 2Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies 3
...: The HF-compatible V series from Pentax, the stan...asured., ,The HF-compatible series of fibre bronc...V and FB-15V models along with the very slim FB-10... quality thanks mainly to the higher resolution an...
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
The BRO-YP2 is Fujinon's pediatric fiberoptic bronchoscope. Its small outside diameter allows for more comfortable transnasal insertion. The standard 2.0mm channel provides sufficient suction and acc
...m the latest 60 series bronchoscopes., ,Olymp... providing clinicians with superior specifications...ressive range of fiberoptic instruments for diagno...he demands of increasing peripheral bronchoscopy.,...
Medicine Products: